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MicroRNA (miR)-21 is an important suppressor of T-cell apoptosis that is
also overexpressed in many types of cancers. The exact mechanisms under-
lying the antiapoptotic effects of miR-21 are not well understood. In this
study, we used the Jurkat T-cell line as a model to identify apoptosis-
associated miR-21 target genes. We showed that expression of miR-21
rapidly increases upon aCD3/aCD28 activation of Jurkat cells. Inhibition
of miR-21 reduced cell growth which could be explained by an increase in
apoptosis. MicroRNA target gene identification by AGO2 RNA-
immunoprecipitation followed by gene expression microarray (RIP-Chip)
resulted in the identification of 72 predicted miR-21 target genes that were at
least twofold enriched in the AGO2-IP fraction of miR-21 overexpressing
cells. Of these, 71 were at least twofold more enriched in the AGO2-IP
fraction of miR-21 overexpressing cells as compared to AGO2-IP fraction of
control cells. The target gene for which the AGO2-IP enrichment was most
prominently increased upon miR-21 overexpression was the proapoptotic
protein LATS1. Luciferase reporter assays and western blot analysis
confirmed targeting of LATS1 by miR-21. qRT-PCR analysis in primary
T cells showed an inverse expression pattern between LATS1 transcript levels
and miR-21 upon T-cell stimulation. Finally, LATS1 knockdown partially
rescued the miR-21 inhibition-induced impaired cell growth. Collectively,
these data identify LATS1 as a miR-21 target important for the antiapoptotic
function of miR-21 in T cells and likely also in many types of cancer.
Introduction
Increased miR-21 levels have been shown in various
types of solid tumors as well as in hematological
malignancies [1–6]. Consistent with the marked overex-
pression in cancer, several studies showed an
Abbreviations
LATS1, large tumor suppressor kinase 1; miRNA, microRNA; RIP-Chip, RNA-binding protein immunoprecipitation–microarray profiling.
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antiapoptotic effect of miR-21. Knockdown of miR-21
correlates with increased apoptosis and reduced prolifer-
ation of breast cancer cells [2,3]. Multiple cancer-
relevant miR-21 target genes, such as tropomyosin 1
(TPM1), programmed cell death 4 (PDCD4), phos-
phatase and tensin homolog (PTEN), Maspin, and
SNF-related, matrix-associated, actin-dependent regula-
tor of chromatin, subfamily A, member 4 (SMARCA4),
have been identified [4–9]. More recent studies also
showed effects of miR-21 on T-cell activation and sur-
vival [10–13]. We previously showed that memory T
cells are characterized by a high expression of miR-21.
In addition, we showed that activation-induced miR-21
provides critical antiapoptotic signals in memory T cells
allowing long-term survival [11,14]. However, the miR-
21 target genes responsible for the protection against
activation-induced apoptosis of T cells remain unknown.
In this study, we set out to investigate miR-21 target
genes related to its antiapoptotic effects on T cells. We
employed an experimental RNA-immunoprecipitation
followed by gene expression microarray (RIP-Chip)-
based approach [15] in Jurkat cells. These cells are a
commonly used model to study regulatory pathways
involved in T-cell activation and apoptosis. We identi-
fied the proapoptotic large tumor suppressor kinase 1
(LATS1) as the miR-21 target gene whose enrichment
in the argonaute 2 immunoprecipitated (AGO2-IP)
increased the most upon miR-21 overexpression and
showed its role in the antiapoptotic effect of miR-21.
Results and discussion
Jurkat is a suitable model to study the
antiapoptotic role of miR-21
To assess if the Jurkat cell line is a suitable model to
study the function of miR-21 in relation to apoptosis,
we determined miR-21 expression levels in unstimu-
lated cells and after stimulation with aCD3/aCD28. In
comparison to other miRNAs known to be expressed
in T cells at high (miR-17) or low (miR-146a) levels,
miR-21 levels were moderate in unstimulated cells
(Fig. 1A). Activation of Jurkat cells with aCD3/
aCD28 for 3 days revealed a marked induction of
miR-21 expression (≥25-fold, P ≤ 0.001; Fig. 1B)
consistent with previous studies on aCD3/aCD28-
stimulated primary T cells [11,13]. To determine
whether loss of miR-21 resulted in a growth defect, we
infected Jurkat cells with a miR-21 inhibitor vector
which coexpresses GFP. GFP analysis over time of a
mixture of transduced and nontransduced cells (GFP
competition assay) revealed a significant decrease of
miR-21 inhibitor-transduced (GFP-positive) cells when
compared to nontransduced (GFP-negative) cells
(Fig. 1C). Cells transduced with three nontargeting
(NT) control inhibitors showed no effect on cell growth
in the GFP competition assay (Fig. 1C and data not
shown). Jurkat cells transduced with miR-21 inhibitor
showed a significant decrease of viable cells starting at
day 4, which was not observed with control transduced
cells (Fig. 1D). This effect was paralleled by an increase
of apoptotic cells reaching > 80% at day 6 (Fig. 1E,F).
These findings are consistent with our reported findings
in primary T cells [11] and indicate that endogenous
levels of miR-21 in Jurkat cells provide an essential
antiapoptotic signal. Together, these data show that the
Jurkat cell line is a suitable model to study the anti-
apoptotic properties of miR-21 in T cells.
miR-21 target genes involved in apoptosis
To identify the antiapoptotic miR-21 target genes, we
performed AGO2-RIP-Chip on Jurkat cells overex-
pressing miR-21 (Jurkat-miR-21) and used cells trans-
duced with an empty vector construct (Jurkat-EV) as a
control. The miR-21 levels showed an increase of
~ 22-fold in Jurkat-miR-21 compared to Jurkat-EV
(Fig. 2A). Overexpression of miR-21 in Jurkat cells
did not cause any obvious effects on the percentage of
live cells (data not shown). The efficiency of the
AGO2 immunoprecipitation (AGO2-IP) as determined
by western blot was comparable between Jurkat-EV
and Jurkat-miR-21 cells (Fig. 2B). As expected, miR-
21 was strongly enriched in the Jurkat-miR-21 AGO2-
IP fraction in comparison to the Jurkat-miR-21 total
fraction and the Jurkat-miR-21 and Jurkat-EV IgG1
control IP fractions. Some miR-21 enrichment could
also be observed in the Jurkat-EV AGO2-IP fraction
as Jurkat cells endogenously express moderate miR-21
levels (Figs. 2C and 1A).
Gene set enrichment analysis (GSEA) [16] revealed a
strong enrichment of multiple microRNA (miRNA)-
binding motifs in both Jurkat-miR-21 (8 of the top 10)
and Jurkat-EV (9 of the top 10, Table 1) further vali-
dating the efficiency of the AGO2-RIP. The miR-21-
binding motif increased from the 46th position of most
enriched gene sets in Jurkat-EV (false discovery rate
(FDR) = 0.0013) to the 28th position in Jurkat-miR-
21 cells (FDR ≤ 0.001). Comparison of both top-10
enriched gene sets revealed a marked overlap between
Jurkat-miR-21 and Jurkat-EV cells with eight shared
gene sets (Table 1). A marked difference was observed
for two apoptosis-related gene sets. Genes regulated
upon treatment with the growth and survival factor,
IL-6, were among the top-10 most enriched gene sets
in Jurkat-EV but not in Jurkat-miR-21 (position 258).
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Genes involved in sensitivity to TRAIL-induced apop-
tosis were found among the top-10 most enriched in
Jurkat-miR-21 but not in Jurkat-EV cells (position
1237). The expression levels of genes represented by
the latter gene set showed an overall decrease in the
total fraction of Jurkat-miR-21 as compared to Jur-
kat-EV (not shown). These differences can be
explained by either direct or indirect effects of miR-21
and fit with the observed antiapoptotic role of miR-21
in Jurkat cells. Comparison of the expression levels of
all predicted miR-21 target genes (209 of 14 514
unique genes) between the total fractions of Jurkat-EV
and Jurkat-miR-21 revealed a systematic decrease in
transcript levels in Jurkat-miR-21 cells (Fig. 3A). This
indicates that transcript levels of predicted miR-21
genes were decreased upon miR-21 overexpression. As
a control, we also analyzed differences in the expres-
sion levels of predicted miR-146a targets (162 of
14 514) and predicted miR-17 targets (929 of 14 514).
No difference was observed for the predicted miR-
146a target genes, while a mild decrease was observed
for predicted miR-17 target genes (Fig. 3A). The latter
observation can be explained by the marked overlap
between the miR-21 and miR-17 predicted target
genes, i.e., 62 shared predicted target genes. In line
with these observations, we noted a specific enrichment
Fig. 1. Validation of the Jurkat cell line as a model to study miR-21 function in T cells. (A) Relative expression of miR-21 in comparison to a
randomly picked miRNA with higher (miR-17) and lower (miR-146a) expression as analyzed by qRT-PCR in Jurkat cells. miRNA expression
was normalized to the expression of RNU48 (shown is the mean  error). (B) miR-21 expression levels in Jurkat cells analyzed by qRT-PCR
with and without aCD3/aCD28 activation. miR-21 expression was normalized to RNU48 (n = 4, Friedman test). Shown is the median with
interquartile range. (C) Relative growth of Jurkat cells as determined by a GFP competition assay. Cells were stably transduced with miR-21
inhibitor and control inhibitor vectors that coexpress GFP. The percentage of GFP+ cells in a mixture of transduced and nontransduced cells
was followed up for 22 days in three independent experiments. The GFP percentage at day 4 of each sample was set to 1. Mean values
with SD are shown (n = 3, mixed model analysis). (D) Percentages of viable Jurkat cells upon transduction with control or miR-21 inhibitor
based on the forward and side scatter pattern obtained by FACS. Mean values with standard error of mean (SEM) are depicted for control
(n = 3) and miR-21 inhibitor (n = 4, two-way repeated measures ANOVA with a Bonferroni post-test). (E) Percentages of apoptotic Jurkat
cells in culture upon transduction with control (n = 2) or miR-21 inhibitor (n = 2). Apoptotic cells were defined by the loss of mitochondrial
transmembrane potential as assessed by FACS analysis using DiLC compound (50 nM). Mean values with SEM are depicted (two-way
repeated measures ANOVA with a Bonferroni post-test). (F) Representative FACS plot depicting the increase of apoptotic cells upon miR-21
inhibition as loss of DiLC staining (day 6). *P ≤ 0.05, ***P ≤ 0.001.
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of predicted miR-21 target genes among the top-1500
genes enriched in the IP of Jurkat-miR-21 (n = 72) as
compared to the IP of Jurkat-EV cells (n = 48). The
enrichment was even more pronounced among the
top-250 enriched genes (n = 20 versus n = 10; Fig 3B).
As a control, we also analyzed enrichment of the pre-
dicted target genes of miR-146a and miR-17, which
revealed no differences between Jurkat-EV and Jurkat-
miR-21 (Fig. 3B). Together, these data show an effi-
cient enrichment of miRNA target genes in the IP
fractions of both conditions and a marked enrichment
of miR-21 predicted target genes in Jurkat cells over-
expressing miR-21.
LATS1 is involved in the antiapoptotic role of
miR-21 in T cells
Seventy-two predicted miR-21 targets were enriched at
least twofold in Jurkat-miR-21 IP as compared to the
total fraction. Seventy-one of these 72 targets were
Fig. 2. Efficiency of AGO2-RISC IP in Jurkat-EV and Jurkat-miR-21 cells. (A) qRT-PCR analysis of miR-21 in Jurkat cells transduced with
empty vector (EV) or miR-21. miR-21 expression was normalized to RNU48 and the level detected in Jurkat-EV was set to 1 (n = 3, median
with interquartile range is shown). (B) Western blot analyses for AGO2 to determine the efficiency of the AGO2-IP using total (T),
Flowthrough (FT) and immunoprecipitated (IP) fractions of Jurkat-EV and Jurkat-miR-21. IP with mouse IgG1 served as a negative control.
(C) qRT-PCR analysis of miR-21 levels in RNA isolated from T, FT, and IP fractions of AGO2- and control IgG1-IP experiments of Jurkat-EV
and Jurkat-miR-21 cells. miR-21 expression was normalized to RNU48 and the level detected in the T of Jurkat-EV was set to 1. miR-21
was enriched in the AGO2-IP fractions of Jurkat-EV and Jurkat-miR-21, and was 86-fold higher in the IP fraction of Jurkat-miR-21 as




AGCACTT, miR-93, miR-302A, miR-302B, miR-302C, miR-302D,
miR-372, miR-373, miR-520E, miR-520A, miR-526B, miR-520B,
miR-520C, miR-520D
2 1
TGAATGT, miR-181A, miR-181B, miR-181C, miR-181D 9 2
GCACTTT, miR-17-5P, miR-20A, miR-106A, miR-106B,
miR-20B, miR-519D
1 3
TTTGCAC, miR-19A, miR-19B 8 4
ACACTAC, miR-142-3P 4 5
GTGCAAT, miR-25, miR-32, miR-92, miR-363, miR-367 6 6
TGCACTT, miR-519C, miR-519B, miR-519A 7 7
TTGCACT, miR-130A, miR-301, miR-130B 10 8
HAMAI_APOPTOSIS_VIA_TRAIL_UP 1237 9
SENGUPTA_NASOPHARYNGEAL_CARCINOMA_WITH_LMP1_UP 106 10
ACTTTAT, miR-142-5P 5 17
ATAAGCT, miR-21 46 28
BROCKE_APOPTOSIS_REVERSED_BY_IL6 3 258
Table 1. Gene set enrichment analysis.
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enriched at least twofold more in the AGO2-IP frac-
tion of Jurkat-miR-21 as compared to the AGO2-IP
fraction of Jurkat-EV. These 71 targets and their gene
ontologies are listed in Table 2 and include 11 previ-
ously confirmed miR-21 target genes (at least by repor-
ter assay). Of these 11, we validated the regulation of
PIK3R1 by miR-21 using luciferase assays and the
upregulation of PDCD4 protein expression upon miR-
21 inhibition in Jurkat cells (data not shown). Within
the 71 target genes identified in this study, six were
related to regulation of apoptosis, i.e., PDCD4, Ras
homology family member B (RHOB), mitogen-activated
protein kinase 1 (MAP3K1), protein kinase C (PRKCE),
RAS P21 protein activator (GTPase-activating protein)
1 (RASA1), and LATS1.
We selected LATS1 for further studies as it showed
the strongest increase in AGO2-IP enrichment upon
miR-21 overexpression (Table 2) and had a known
function related to apoptosis [17,18]. In addition, it
was recently shown that miR-21 can target LATS1 in
cervical cancer [19]. We identified one 8-mer and two
7-mer miR-21-binding sites in the 30UTR of LATS1
(Fig. 4A). Luciferase reporter assays with two
constructs including either the 8-mer or the two 7-mer
miR-21-binding sites consistently showed significant
increases in luciferase activity, thereby demonstrating
that LATS1 is a bona fide miR-21 target (Fig. 4B). In
agreement with this finding, inhibition of miR-21 in
Jurkat cells increased the expression of LATS1 protein
(Fig. 4C).
To determine the relevance of the increase of
LATS1 for the miR-21 inhibition-induced phenotype
(Fig. 1C), we studied the effect of miR-21 inhibition in
LATS1-knockdown (KD) cells. Stable LATS1-KD
cells were generated by infection of Jurkat cells with
lentiviral LATS1-shRNA constructs or NT control
shRNA vectors. Western blotting for LATS1 in sorted
LATS1-KD cells showed that the efficiency of the
shRNAs ranged between 70% and 90% (Fig. 5A).
Next, we infected the LATS1-KD and control cells
with miR-21 inhibitor and control inhibitor virus, con-
taining GFP and monitored the GFP percentage over
time within the LATS1-KD cells. As expected, miR-21
inhibition caused a strong reduction in the percentage of
GFP+ cells in the NT shRNA-infected and wild-type
cells with on average 15% of GFP+ cells left after
Fig. 3. Transcript levels of predicted miR-21
targets are more enriched in the AGO2-IP
fraction and depleted in total fraction upon
miR-21 overexpression. (A) Bland–Altman
plots comparing the expression levels of
miR-21, miR-146a, and miR-17 predicted
target genes in the total fractions of Jurkat-
EV and Jurkat-miR-21. The expression
difference of each gene is plotted against
its mean expression. Red lines represent
the best fit to the data. (B) Percentages of
predicted miR-21, miR-146a, and miR-17
target genes in all 14 514 expressed genes
and in the top-1500 and top-250 most
enriched genes in the AGO2-IP fractions of
Jurkat-EV and Jurkat-miR-21. Filled bars
represent miR-21 IP, open bars represent
EV IP.
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Table 2. Functional annotation of 71 predicted miR-21 target genes with ≥2-fold increase in IP enrichment upon miR-21 overexpression.
Gene symbol EV IP/T miR-21 IP/T miR-21/EV
Proven
target Annotation
LATS1 4.8 126.9 26.6 [19] Apoptosis induction, cell cycle inhibition, serine/threonine kinase activity
FAM63B 1.2 19.3 16.5 Phosphoprotein
MBNL1 2.2 34.7 15.8 RNA splicing regulation
TRPM7 1.9 21.8 11.3 Transmembrane protein, cation channel activity
CDK6 0.8 7.8 9.7 [1] Cell cycle regulation, cyclin-dependent protein kinase activity, p53
signaling pathway
RAB22A 0.8 6.4 7.9 Intracellular signaling cascade, GTPase activity
PAG1 0.9 7 7.8 Immune system, inhibition of lymphocyte activation, molecular
adaptor activity
TET1 1.7 13.4 7.8 Oxidoreductase activity
BMPR2 2.5 19.8 7.8 [27] Phosphorylation induction, serine/threonine kinase activity
PLAG1 7.8 61.2 7.8 Transcription regulation, transcription factor activity
STAG2 0.9 6.5 7.4 Cell cycle regulation, chromosome segregation, mitosis, meiosis
FAM126B 2.4 17.2 7.2 Phosphoprotein
UBN2 1.7 11.8 7 Phosphoprotein
PIK3R1 1.3 9.3 6.9 [28] Immune system development, lymphocyte activation, TCR signaling
YOD1 2.8 19.6 6.9 Proteolysis, peptidase activity
RPS6KA3 0.6 4.1 6.5 Serine/threonine kinase activity, MAPK signaling pathway
NFAT5 2 12.7 6.4 Immune system, transcription induction, transcription factor activity,
TCR signaling
FBXO28 3 18.1 6.1 Proteolysis
LCORL 1.3 7.7 6.1 Transcription regulation
PDCD4 0.9 5.3 5.7 [1,29,30] Apoptosis induction, cell cycle inhibition, inhibition of kinase activity
PAN3 4.1 23.5 5.7 mRNA catabolism process, protein kinase activity
MSL1 0.9 5.3 5.6 Chromatin organization
PLEKHA1 6 31.3 5.3 Enzyme-linked receptor protein signaling pathway
AP4E1 1 5.1 5.3 Intracellular protein transport
KLHL15 3.4 17.8 5.3 Na
PBRM1 0.7 3.7 5.2 Cell cycle regulation, chromatin regulator
ZYG11B 0.8 4.1 5.1 Proteolysis
CPEB3 4.2 20.9 5 RNA binding
PRPF4B 1 4.8 5 RNA processing, serine/threonine kinase activity
PIKFYVE 0.8 3.9 4.9 Intracellular signaling cascade, phosphatidylinositol signaling system
SATB1 1.5 7.3 4.8 Transcription inhibition, chromatin organization
RASGRP1 1 4.6 4.7 [31] Immune system, intracellular signaling cascade, TCR signaling
FBXO11 1.2 5.6 4.6 [32] Proteolysis, ubiquitin ligase complex
PURB 1.5 6.9 4.6 Transcription inhibition, transcription factor activity
WWP1 2 9 4.4 Proteolysis, ubiquitin ligase complex
TOPORS 0.9 3.8 4.4 [33] Proteolysis, response to DNA damage stimulus
FAM3C 4.7 20.3 4.3 Cytokine activity
BCL11A 2.8 12.2 4.3 Immune system development, lymphocyte activation, transcription
repressor activity
C10orf12 0.8 3.5 4.3 Phosphoprotein
KLF12 1 4.1 4.3 Transcription regulation, transcription factor activity
CHIC1 3.2 13.5 4.2 Cytoplasmic membrane-bounded vesicle
SLC10A7 2.5 10.2 4.1 Ion transport, organic acid: sodium symporter activity
RASA1 1.6 6.2 3.9 [31,34] Apoptosis inhibition, GTPase activity, MAPK signaling pathway
SECISBP2L 1.7 6.4 3.9 Phosphoprotein
FRS2 5.4 20.6 3.8 Cell–cell signaling, phosphorylation regulation, phosphatase regulator activity
TRIM33 1 3.9 3.7 Transcription inhibition
EIF2C4 1.1 4.2 3.7 Translation inhibition, ribonucleoprotein complex
ZNF217 3.3 12 3.6 Transcription regulation, transcription factor activity
CHD7 1 3.6 3.5 Immune system development, lymphocyte activation, helicase activity
NFIA 1.1 3.9 3.4 Transcription regulation, transcription factor activity
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Table 2. (Continued).
Gene symbol EV IP/T miR-21 IP/T miR-21/EV
Proven
target Annotation
SKI 2.5 8.1 3.3 Transcription inhibition, transcription factor activity
C5orf41 7.5 24.5 3.3 Transcription regulation, transcription factor activity
ZNF367 13.7 38.5 2.8 Transcription regulation, transcription factor activity
EIF4EBP2 3.3 9.3 2.8 Translation inhibition
RECK 2.7 7.5 2.8 [35] Vasculature development, peptidase inhibitor activity
MARCH5 2.9 7.5 2.6 Proteolysis
TNRC6B 1.4 3.6 2.6 Translation inhibition, ribonucleoprotein complex
RHOB 1.9 4.8 2.5 [36] Apoptosis induction, cell cycle inhibition, GTPase activity
AP3M1 1.4 3.6 2.5 Intracellular protein transport
ATPAF1 2.1 5.2 2.5 Protein complex assembly, mitochondrion
KBTBD6 1.9 4.7 2.5 Proteolysis
PPP1R3B 2 4.8 2.4 Insulin signaling pathway, glucose metabolism process
ZFP36L2 2.5 6 2.4 mRNA stability regulation, transcription factor activity
BCL7A 2.7 6.5 2.4 Transcription inhibition
MAP3K1 1.5 3.4 2.3 Apoptosis induction, stress-activated protein kinase signaling,
MAPK signaling
C17orf39 2.7 6.3 2.3 Na
CNOT6 1.8 4.2 2.3 Transcription regulation, nuclease activity
CD69 31.9 72.6 2.3 Transmembrane protein
KLF3 2.1 4.4 2.1 Transcription regulation, transcription factor activity
PRKCE 2.1 4.1 2 Apoptosis inhibition, calcium-independent protein kinase C activity
SLC7A6 1.8 3.7 2 Organic acid transport, amino acid transmembrane transporter activity
Fig. 4. Luciferase reporter assay for LATS1 30UTR. (A) Schematic presentation of the location of the miR-21-binding sites in the 30UTR of
LATS1 and the regions cloned into the reporter vector. Binding site sequences are shown in the lower part. (B) Luciferase reporter assay shows
that miR-21 can bind to the miR-21-binding sites in LATS1. Plotted is the ratio of Renilla luciferase (RL) to firefly luciferase (FL) signal detected in
lysates of Cos-7 cells transfected with psiCHECK-2 construct and cotransfected with miR-21 inhibitor (closed bars) or control inhibitor (open
bars). Shown per condition is the mean with SD (n = 5, unpaired t-test) (C) Quantification of LATS1 protein levels in Jurkat cells transduced with
control or miR-21 inhibitor. Results from two independent experiments are shown, analyzed by western blot. A representative image of each
experiment is shown. GAPDH was used as internal control. LATS1 to GAPDH ratio in control inhibitor-infected cells was set to 1. *P ≤ 0.05,
**P ≤ 0.01.
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22 days (Fig. 5B). Knockdown of LATS1 was found to
partially rescue this effect as a more than 2.5-fold higher
percentage of GFP+ cells was left (average of the three
shRNAs, 38%) after 22 days of miR-21 inhibition
(P-value ≤ 0.05, Fig. 5B). These results show that the
proapoptotic effect observed upon miR-21 inhibition is
at least in part mediated by downregulation of LATS1.
To study the relevance of the miR-21–LATS1 axis in
primary T cells, we analyzed LATS1 and miR-21 levels
of primary sorted na€ıve T cells (CD4+CD45RO-) stimu-
lated for 3 days with a-CD3 and a-CD28. This revealed
an inverse pattern, i.e., increased levels of miR-21 and
decreased levels of LATS1 upon stimulation (Fig. 6A,
B). The increase of miR-21 upon stimulation supports
our previous findings and those of others [11–13,20].
The inverse expression pattern of LATS1 suggests that
targeting of LATS1 by miR-21 is highly relevant for sur-
vival of primary T cells. We also studied miR-21 and
LATS1 expression in sorted na€ıve (CD4+CD45RO-)
and memory (CD4+CD45RO+) T cells. In line with
what we and others have previously shown, we observed
higher levels of miR-21 in memory T cells compared to
na€ıve T cells (Fig. 6C) [11,12,20]. However, we did not
observe decreased LATS1 transcript levels in memory T
cells as compared to na€ıve T cells (Fig. 6D). This sug-
gests that miR-21 does not lower the LATS1 RNA
levels in memory cells, but regulates LATS1 protein
level by post-transcriptional repression of protein trans-
lation. To confirm regulation of LATS1 protein levels
by miR-21 specifically in memory T cells, LATS1 pro-
tein analysis in na€ıve and memory T cells as well as
AGO2-RIP experiments should be performed.
In summary, we showed that the Jurkat cell line is a
suitable model to study the role of miR-21 in the regu-
lation of T-cell apoptosis. We experimentally identified
multiple miR-21 target genes via employing AGO2-
RIP-Chip, including the proapoptotic LATS1 gene.
We showed that LATS1 is a bona fide miR-21 target
whose knockdown can at least partially rescue the
proapoptotic effect of miR-21 inhibition. Thus, LATS1
is likely to be an important target for the antiapoptotic
role of miR-21 in (activated) T cells, possibly in com-
bination with other targets such as PDCD4. As miR-
21 is widely overexpressed in a variety of cancers, it is
also of interest to further study the relevance of the
miR-21 target LATS1 in relation to cancer.
Fig. 5. LATS1 knockdown can partially rescue the miR-21 inhibition-induced impaired cell growth phenotype. (A) Analysis of LATS1 protein
levels upon knockdown in Jurkat cells. Jurkat cells were stably infected with shRNA constructs targeting LATS1 or NT control shRNAs and
sorted based on dsRED fluorescence. WT = wild-type. LATS1 levels relative to GAPDH are shown below. (B) LATS1 knockdown cells are
less susceptible to miR-21 inhibition-induced impaired growth. Sorted LATS1 KD cells (sh1-sh3, black bars) and controls (NT1, NT2, and WT,
white bars) were infected with miR-21 inhibitor or control inhibitor cells. miR-21 or control inhibitor-infected cells were followed based on
GFP fluorescence, and the GFP percentage within the LATS1 knockdown cells was monitored till day 22 post infection. For each sample,
the GFP percentage at day 4 was set to 100% and the relative percentage at day 22 post infection is indicated. The GFP percentage
remains unaffected in control inhibitor-infected cells. In contrast, most GFP+ cells are gone in miR-21 inhibitor-infected cells. LATS1
knockdown cells have on average more than 2.5-fold more GFP+ cells left than the controls indicating that LATS1 knockdown can partially
rescue the miR-21 inhibition-induced phenotype. Shown is the mean with SD (n = 2, unpaired t-test). *P-value ≤ 0.05.
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Materials and methods
Cell lines
The Jurkat, human acute leukemic T-cell line was cultured
in RPMI 1640 supplemented with 10% fetal bovine serum
(FBS), 200 mM L-glutamine, 100 mM Na-pyruvate,
10 mgmL1 gentamycin (Lonza, Breda, The Netherlands),
0.05 M b-mercapto-ethanol (Merck, Darmstadt, Germany)
at 37 °C in 5% CO2. The SV40 large T-antigen-
transformed human embryonic kidney cell line, HEK293T,
and Phoenix-Ampho were cultured in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 10% FBS,
200 mM L-glutamine, and 10 mgmL1 gentamycin sulfate
(Lonza) at 37 °C in 5% CO2. African Green Monkey
SV40-transformed kidney fibroblast cell line COS-7 was
cultured in DMEM supplemented with 10% FBS (Thermo
Scientific, Breda, The Netherlands), 200 mM L-glutamine,
and 10 mgmL1 gentamycin sulfate at 37 °C in 5% CO2.
Cell lines were obtained from ATCC. We routinely con-
firmed the identity of our cell lines using the PowerPlex 16
HS System (Promega, Leiden, The Netherlands).
T-cell activation with aCD3/aCD28 monoclonal
antibodies (mAbs)
Stimulation of Jurkat T cells was performed with plate-
bound anti-CD3 and soluble anti-CD28 mAbs. Briefly, cul-
ture plates were incubated with goat anti-mouse-IgG2a Ab
(Cat. No. 1080-01, Southern Biotechnology, Uden, The
Netherlands) overnight at 4 °C, followed by washing with
PBS and 1-h incubation with hybridoma-culture super-
natant, containing anti-human-CD3 IgG2a mAb (clone
WT32, concentration ~ 1 lg IgGmL1) at RT. Unbound
anti-CD3 antibody was removed by washing 4 times with
an excess of PBS. Cells were seeded at a density of
0.25 9 106 cellsmL1 in medium supplemented with 5%
V/V hybridoma-culture supernatant containing anti-CD28
IgG1 mAb (clone 20-4669), resulting in a final concentra-
tion of 0.1 lg IgGmL1. At the indicated time points, cells
were harvested, lyzed with Qiazol reagent (Qiagen, Venlo,
The Netherlands), and stored at 20 °C. Primary CD4+ T-
cell isolation and stimulation was described earlier [20,21].
All participants provided written informed consent accord-
ing to the Declaration of Helsinki to participate in this
study which was approved by The Medical Ethical Com-
mittee (METC; project number: 2009.118) of the University
Medical Center Groningen UMCG.
Viral constructs
To generate the lentiviral miR-21 overexpression construct,
pre-miR-21 with ~ 150 nucleotides of the flanking sequence
was amplified from genomic DNA using forward 50-gtcagaa-
tagaatagaattgggg-30 and reverse 50-gctgcattatggcacaaaag-30
primers. NheI and XhoI restriction sites were added to the
forward primer and an EcoRI site was added to the reverse
primer to allow directional cloning into the retroviral MXW-
PGK-IRES-GFP vector [22] using standard laboratory proce-
dures. To stably inhibit miR-21 function, we used a lentiviral
miR-21 inhibition vector (pmiRZip-21; Cat. Nr: MZIP21-PA-
1) and three NT lentiviral inhibitor vectors (control inhibitor,
Cat. Nr: MZIP000-PA-1, both from Systems Biosciences,
Mountain View, USA and shNT1 and shNT2, see below) as
controls. The sequences of shRNAs against LATS1 and con-
trols used for cloning to the BamHI and EcoRI sites of the
lentiviral pDsREDPuro vector (MZIP/pGreenPuro vector
with the copGFP replaced by dsRED, Systems Biosciences)
are as follows: LATS1-sh1-S: 50GATCCGCTGCTCCT
TCGTCATATACATTCAAGAGATGTATATGACGAAGG
Fig. 6. Expression of miR-21 and LATS1 in
primary CD4+ T cells. Analysis of (A) miR-21
and (B) LATS1 mRNA expression in
CD3+CD4+CD45RO- naive T cells before
and after 3 days of stimulation with aCD3/
CD28. Analysis of (C) miR-21 and (D) LATS1
expression in sorted CD3+CD4+CD45RO-
na€ıve and CD3+CD4+CD45RO+ memory T
cells. miR-21 expression was normalized to
RNU44, and LATS1 levels were normalized
to TBP. Data are presented as relative
expression and medians are indicated as a
horizontal line (panel A and B: n = 5, panel
C and D: n = 8, Mann–Whitney test).
*P ≤ 0.05, ***P ≤ 0.001.
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Virus production and viral transduction
Lentiviral particles were produced with a third-generation
lentiviral system in 293T cells by CaPO4 transfection as
described previously [23]. Lentiviral transduction of Jurkat
cells was carried out for 24 h in the presence of 4 lgmL1
polybrene (Sigma-Aldrich, St. Louis, USA).
Retroviral particles were produced by calcium phosphate
(CaPO4)-mediated transfection of Phoenix-Ampho packag-
ing cells with 10 lg pMXW-PGK-IRES-GFP-miR-21 (miR-
21 overexpression) or pMXW-PGK-IRES-GFP-EV (con-
trol) and 0.63 lg of pSuper-DGCR8 in T25 flask. Retroviral
particles were collected 48 h after transfection, passed
through a 0.45 lm Millex-HV filter (Millipore, Amsterdam,
The Netherlands) and concentrated with Retro-X concentra-
tor (Clontech, Saint-Germain-en-Laye, France) according to
the manufacturer’s protocol. Jurkat cells were transduced
with the virus by spinning at 1200 g for 2 h.
GFP competition assay
GFP percentage of pmiRZip-21- or pmiRZip-scrambled-
infected Jurkat cells was followed over a period of 22 days. The
starting GFP percentage varied between 30% and 40%. Data
were acquired on FACS Calibur flow cytometer (BD Bios-
ciences, San Jose, CA, USA) and analyzed using FLOWJO soft-
ware (version 7.6, Treestar, Ashland, OR, USA). The GFP
percentage analyzed at the first day of measurement (day 4) was
set to 1. The GFP competition assay was performed 3 times.
Apoptosis measurement
Percentages of apoptotic cells were assessed in Jurkat cells
transduced with miR-21 or control inhibitor in > 95% of
the cells on day 4, 6, and 8 following viral transduction by
FACS-based measurement of mitochondrial transmem-
brane potential loss. Briefly, cells were stained for 20 min
at 37 °C in cell culture medium containing 50 nM DiLC1
(Enzo Life Sciences, NY, USA), which was followed by a
washing step with PBS. Cells were kept on ice and DiLC1
staining was measured at the FACS Calibur flow cytometer
using Cell Quest software (BD Biosciences). Data were ana-
lyzed using Kaluza Flow Analysis Software (Beckman
Coulter).
Quantitative RT-PCR
Total cellular RNA was extracted using the miRNeasy
Mini Kit (Qiagen) following the manufacturer’s instruc-
tions. The RNA quantity was measured on a NanoDrop
ND-1000 Spectrophotometer (Thermo Scientific).
MicroRNA expression levels were determined by quanti-
tative RT-PCR. RNA was reverse transcribed using the
Taqman miRNA Reverse Transcription kit in combination
with multiplexed reverse transcription primers of TaqMan
miRNA assays (Thermo Scientific): for miR-21-5p (ID:
000397), miR-17 (ID: 002308), miR-146a (ID: 000468),
RNU48 (ID: 001006), RNU44 (ID: 001094) [24]. RNU44
and 48 served as reference genes to normalize miRNA
expression levels. The qPCR reaction was performed using
qPCR MasterMix Plus (Eurogentec, Liege, Belgium).
cDNA synthesis for mRNA was performed using Super-
script III RTase (Thermo Scientific). The qPCR reaction
was performed using qPCR MasterMix Plus. Taqman gene
assay was used for detection of LATS1: Hs01125523_m1;
Thermo Scientific). Primers and probe (Integrated DNA
Technologies, Coralville, USA) used for detection of TBP
were as follows: forward 50-GCCCGAAACGCCGAAT
AT-30, reverse 50-CCGTGGTTCGTGGCTCTCT-30. Mean
cycle threshold (Ct) values were quantified with the
Sequence Detection Software (SDS, version 2.3, Thermo Sci-
entific), using ABI7900HT thermo cycler (Thermo Scien-
tific). Relative expression levels were determined using the
2DCt formula, where DCt = Ctgene  Ctref.gene.
AGO2-RIP-Chip procedure
Immunoprecipitation of AGO2-containing RISC complexes
was performed as described previously by Tan et al. [15]
and Slezak-Prochazka et al. [25]. Briefly, cleared lysates of
40 million cells were incubated with protein G Sepharose
beads (GE Healthcare, Eindhoven, The Netherlands)
coated with anti-AGO2 antibody (Clone 2E12-1C9,
Abnova, Taiwan) at 4 °C overnight. IP with anti-IgG anti-
body was used as a negative control (Millipore BV, Ams-
terdam, The Netherlands). After washing the beads, RNA
was harvested for microarray and qRT-PCR analysis and
protein lysates were prepared for western blot. RNA from
total (sample taken before start of the IP procedure), flow
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through (FT; sample taken of the supernatant after collec-
tion of the IP fraction), and IP fractions was isolated with
miRNeasy Mini kit (Qiagen) according to the manufac-
turer’s protocol. RNA from total and AGO2-IP fractions
of Jurkat-miR-21 and Jurkat-EV cells was used for
microarray analysis. Labeling and hybridization were per-
formed using two-color Low Input Quick Amp Labeling
Kit, according to the manufacturer’s protocol (Agilent,
Santa Clara, USA). Briefly, 40–100 ng of RNA from T and
AGO2-IP samples was used for cDNA synthesis, followed
by cRNA amplification and Cy-3 and Cy-5 labeling. cRNA
was purified with RNeasy Kit (Qiagen) and quantified on
NanoDropTM ND-1000 Spectrophotometer (Thermo Scien-
tific). Equal amounts of cRNA Cy-3 and Cy-5-labeled sam-
ples were combined and hybridized at 65 °C for 17 h on
the 60k SurePrint G3Human Whole Genome Oligo
Microarray (Agilent). Next, slides were washed and
scanned with SureScan Dx Microarray Scanner (Agilent).
Scanned images were used for Agilent Feature Extraction
software version 10.5, converted into Linear and Lowess
normalized data. Quality control report was generated for
each array. Using GeneSpring GX version 12.5 (Agilent),
quantile normalization of the signals was performed. Next,
probes not detected in more than half of the samples and
probes that are inconsistent (more than twofold different)
in Cy-3 and Cy-5 replicates of the same sample were fil-
tered out. The averaged signals for Cy-3 and Cy-5 repli-
cates were used to calculate the IP/T ratio for each sample.
The microarray data have been deposited in NCBI’s Gene
Expression Omnibus (GSE85116).
Western blotting
Cells were lyzed in Cell Lysis buffer (Cat. # 9803, Cell Sig-
naling Technologies, Leiden, The Netherlands) and incu-
bated on ice for 45 min, centrifuged at 14 000 g, 4 °C and
supernatant was collected. Protein concentration was deter-
mined using DC Protein Assay following the manufac-
turer’s instructions (Bio-Rad Laboratories, Hercules, USA).
Samples were separated on 10% polyacrylamide gels and
transferred onto nitrocellulose membranes. Membranes
were blocked using Odyssey blocking buffer (LI-COR Bio-
sciences, Nebraska, USA). For the detection of LATS1,
rabbit polyclonal anti-human-LATS1 antibody (ab 70562;
Abcam, Cambridge, UK) was used in a dilution of 1 : 250
and incubated overnight at 4 °C. LATS1 expression was
visualized with secondary polyclonal antibody goat anti-
rabbit peroxidase (GaRPO) 1 : 1000 incubated at RT for
an hour (Dako, Leuven, Belgium) and a tertiary rabbit-
anti-goat peroxidase (RAGPO) incubation step (1-h incu-
bation, 1 : 1000 at RT; Dako). The GAPDH antibody
(Santa Cruz Biotechnology, Santa Cruz, USA) was used in
a 1 : 20 000 dilution and staining was visualized with sec-
ondary polyclonal rabbit-anti-mouse peroxidase (RaMPO,
1 : 1000). All antibodies were diluted in Odyssey blocking
buffer supplemented with 0.1% Tween-20. Immunoblots
were incubated with primary antibodies at 4 °C overnight.
Secondary polyclonal goat anti-mouse antibody conjugated
with IRdye 680, and polyclonal goat anti-rabbit antibody
conjugated with IRdye 800 (both from LI-COR Bio-
sciences) were used. Signal was detected with the Odyssey
Infrared Imaging System, Odyssey CLx, and protein bands
were visualized and quantified with IMAGE STUDIO software
version 2.0.38 (both from LI-COR Biosciences). Western
blot for AGO2 was performed as described previously [25].
Cloning of 30-UTRs in reporter constructs,
transient transfection, and luciferase assays
30UTR sequences of LATS1 (LATS1.1/LATS1.2) harboring
miR-21-binding sites were PCR amplified from genomic
DNA using primers with an XhoI (forward) or Notl (reverse)
restriction site, for LATS1.1 forward: 50-AAGGAGA
AACCTGGTATCTAT-30, reverse 50-GAAACTAAGGAA
TACAGGG-30 and LATS1.2 forward: 50-AAATTGCTGA
TACCAAAGG-30, reverse 50-GGAGGGGACTGAAATG
TTAGG-30 and cloned into psiCHECK2 vector (Promega,
Madison, USA), as previously described [26]. The inserts
were sequence verified (BaseClear, Leiden, The Netherlands).
About 1.2 9 104 Cos-7 cells were transfected with 125 ng of
the psiCHECK2 construct and 50 nM miR-21 inhibitor,
molecule ID: 4102261-101 or Negative Control #1 inhibitor,
(Exiqon, Vedbaek, Denmark), using the Saint-MIX com-
pound (Synvolux Therapeutics B.V., Groningen, The
Netherlands), in 250 ll serum-free medium. Four hours fol-
lowing the transfection, 500 ll of medium supplemented
with 10% FBS was added. Cells were lysed 24 h after trans-
fection, and Renilla and firefly luciferase activity was mea-
sured using the Dual-Luciferase Reporter Assay System
(Promega, Leiden, The Netherlands) according to the manu-
facturer’s instructions. For each transfection, luciferase activ-
ity was measured in duplicate with the Luminoscan Ascent
Microplate Luminometer (Thermo Scientific). The renilla
(RL) over firefly (FF) luciferase ratio for miR-21 inhibitor
was calculated. The RL/FF ratio of negative control was set
to a value of 1. Transfections were performed in triplicate.
Prediction of miRNA target genes
The miRNA target prediction program TARGETSCAN 6.2
(http://www.targetscan.org/) was used to determine pre-
dicted target genes of miR-21 (307 conserved genes), miR-
146a (224 conserved genes), and miR-17 (1.220 conserved
genes).
Functional annotation analysis
The functional annotation of genes was performed using the
DAVID BIOINFORMATIC RESOURCES 6.7 (https://david.ncifcrf.
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gov/), based on the following GO categories: GOTERM_BP_-
FAT, GOTERM_CC_FAT, GOTERM_MF_FAT, KEGG_-
PATHWAY, and SP_PIR_KEYWORDS. About 1–4 GO
terms were considered for description of each gene.
Gene set enrichment analysis
Gene sets significantly enriched in the AGO2-IP in compar-
ison to T fraction of Jurkat-EV and Jurkat-miR-21 were
determined by the GSEA using the Molecular Signatures
Database (GSEA; http://software.broadinstitute.org/gsea/
index.jsp) [16]. Lists containing the expression values of
14 415 genes detected in IP and total fractions of Jurkat-
EV or Jurkat-miR-21 were uploaded for the analysis.
Statistical analysis
For comparison of qRT-PCR data of nonstimulated and
stimulated Jurkat cells, we applied the Friedman repeated
measurements nonparametric test. Data from day 0 were
compared to other days of stimulation (days 1, 2, 3). For
comparison of viable and apoptotic Jurkat cells upon
transduction with control or miR-21 inhibitor, we applied
two-way repeated measures ANOVA with a Bonferroni
post-test. To determine whether miR-21-inhibited cells
have a significant impaired cell growth as compared to
control inhibitor-infected cells, we performed mixed model
analysis as described previously [25]. Significance for (RL/
FL) luciferase ratios between control and miR-21 inhibitor
was calculated using unpaired t-test. The same test was
used to determine whether the remaining percentages of
GFP+ cells in LATS1-KD group (LATS1 sh1-3) infected
with a miR-21 inhibitor were significantly different from
the remaining GFP percentages within the controls group
(wild-type, NT1 and NT2) infected with a miR-21 inhibi-
tor. For comparisons of LATS1 and miR-21 in nonstimu-
lated and stimulated CD4+ T cells, we applied the Mann–
Whitney test. Statistical analysis were performed with GRAPH-
PAD Prism version 5.0 (GRAPHPAD Software, San Diego, CA,
USA) or SPSS Statistics version 22.0 (IBM Corp. Armonk,
NY, USA).
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